饶峰 但汉卿

【摘要】 目的：分析血清尿激酶型纤溶酶原激活物（uPA）水平在卵巢上皮性癌化疗患者中的变化及临床意义。方法：以笔者所在医院2018年6月-2019年6月收治的50例卵巢上皮性癌患者为研究对象，均予以TP化疗方案，分别在化疗前后检测其血清uPA水平;比较不同类型患者化疗前后血清uPA水平。结果：不同病理类型、病理分期、分化程度、淋巴结转移患者化疗后血清uPA水平均低于化疗前，差异均有统计学意义（P<0.05）;非浆液性癌、Ⅰ或Ⅱ期、低中分化、淋巴结无转移患者化疗前后血清uPA水平均低于浆液性癌、Ⅲ或Ⅳ期、高分化、淋巴结转移患者，差异均有统计学意义（P<0.05）。结论：经化疗后，卵巢上皮性患者血清uPA水平有所下降。血清uPA水平变化在卵巢上皮性癌化疗患者中的实践，可为患者预后评估提供可靠依据。

【关键词】 卵巢上皮性癌 化疗 血清尿激酶型纤溶酶原激活物

doi：10.14033/j.cnki.cfmr.2020.17.058 文献标识码 B 文章编号 1674-6805（2020）17-0-03

Changes and Clinical Significance of Serum uPA Levels in Patients with Ovarian Epithelial Cancer after Chemotherapy/RAO Feng， DAN Hanqing. //Chinese and Foreign Medical Research， 2020， 18（17）： -138

[Abstract] Objective： To analyze the changes and clinical significance of serum urokinase-type plasminogen activator （uPA） levels in chemotherapy patients with ovarian epithelial cancer. Method： A total of 50 patients with epithelial ovarian cancer admitted to the authors hospital from June 2018 to June 2019 were studied， they were all given TP chemotherapy regimen， and their serum uPA levels were measured before and after chemotherapy， the serum uPA levels of different types of patients were compared before and after chemotherapy. Result： The serum uPA level of patients with different pathological types， pathological stages， degree of differentiation and lymph node metastasis after chemotherapy were lower than those before chemotherapy， the differences were statistically significant （P<0.05）. The serum uPA levels in patients with non-serous cancer， stage Ⅰ or Ⅱ， low in moderately differentiated， and no lymph node metastasis before and after chemotherapy were lower than those in patients with serous cancer， stage Ⅲ or Ⅳ， highly differentiated， and lymph node metastasis， the differences were statistically significant （P<0.05）. Conclusion： After chemotherapy， the serum uPA level in patients with epithelial ovaries has decreased. The change of serum uPA level in patients with chemotherapy for epithelial ovarian cancer can provide a reliable basis for patient prognosis evaluation.

[Key words] Epithelial ovarian cancer Chemotherapy Serum urokinase-type plasminogen activator

First-authors address： Chibi Peoples Hospital， Chibi 437300， China

卵巢上皮性腫瘤是一种十分常见的卵巢肿瘤，在原发性卵巢肿瘤中占比50%～70%，于卵巢恶性肿瘤中占比85%～90%，好发于中老年女性。因该病发病较为隐匿，仅有10%患者在早期确诊，多数患者确诊时已到中晚期，此时其5年生存率只有25%左右。恶性肿瘤转移及侵袭是造成患者死亡及肿瘤复发的重要原因，血清uPA是实现细胞外基质降解的主要蛋白酶水解类，其可降级细胞外基质与基底膜成分，并能经细胞内信号通路，影响肿瘤的血管生成与细胞增殖。有关学者认为，uPA可能于卵巢上皮性癌的早期扩散中发挥着重要作用[1]。另外，文献[2]也表示，uPA水平的高低和肿瘤转移、侵袭与患者预后有密切的联系。鉴于此，为进一步探究血清uPA水平于卵巢上皮性癌化疗患者中的变化与临床意义，现对笔者所在医院50例卵巢上皮性癌患者展开研讨，详细如下。

1 资料与方法

1.1 一般资料

选择笔者所在医院2018年6月-2019年6月收治的50例卵巢上皮性癌患者作为本次研究对象。……